Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Capricor Therapeutics (CAPR) reported a Q3 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.34 loss. This is a larger loss compared to $0.25 per share a year ago.
November 13, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Capricor Therapeutics reported a larger-than-expected Q3 loss of $0.38 per share, missing the consensus estimate and showing a year-over-year increase in losses.
The reported loss per share of $0.38 is worse than the expected $0.34, indicating underperformance. The increase in loss from $0.25 a year ago suggests deteriorating financial health, likely leading to negative short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100